BioAtla, Inc. develops conditionally active biologics (CABs) for the treatment of solid tumor cancers. The company’s proprietary CAB technology exploits the acidic pH of the tumor microenvironment to enable antibodies to bind selectively to cancer cells while remaining inactive in normal tissue. This approach aims to improve the therapeutic window of antibody-based therapies by reducing on-target, off-tumor toxicity. BioAtla’s pipeline includes antibody-drug conjugates, bispecific T-cell engagers, and immuno-oncology candidates targeting antigens such as AXL, ROR2, CTLA-4, and EpCAM. The company leverages its protein discovery platform, based on the Protein-activated Chemical Switch (PaCS) mechanism, to generate a broad range of product candidates, including monoclonal antibodies, ADCs, and CAR-T cells. By linking cytotoxic payloads or T-cell engaging domains to CAB antibodies, BioAtla seeks to deliver potent anti-tumor activity with a improved safety profile.

BioAtla generates revenue primarily through collaboration and licensing agreements with pharmaceutical partners. The company has entered into clinical trial collaborations with Bristol-Myers Squibb to evaluate mecbotamab vedotin and ozuriftamab vedotin in combination with nivolumab. A global co-development agreement with BeiGene provided upfront payments of $25 million for the evalstotug program before its termination. Additionally, BioAtla holds an amended and restated exclusive rights agreement with Himalaya Therapeutics that entitles the company to potential upfront payments, milestones, and royalties for CAB antibodies in Greater China and worldwide for a HER2-bispecific. A recent license agreement with Context Therapeutics grants worldwide rights to a Nectin-4 x CD3 bispecific and could yield up to $133.5 million in aggregate payments, including an upfront cash component and tiered royalties. The company also receives research funding and reimbursement for certain development activities under these partnership agreements. While the company has not yet commercialized any product, these partnership arrangements constitute its current source of income.

BioAtla operates in the highly competitive oncology biotechnology sector, where numerous large and mid-sized companies develop antibody-drug conjugates, bispecific antibodies, and immunomodulatory therapies. Competitors include established players such as Roche, Merck & Co., and Bristol-Myers Squibb, as well as specialized biotechs like Seagen, AstraZeneca’s MedImmune unit, and various ADC-focused firms. The company’s competitive advantage stems from its proprietary CAB platform, which provides tumor microenvironment-restricted binding to reduce systemic toxicity while maintaining potency. This differentiated mechanism aims to expand the range of druggable targets that have been deemed undruggable due to expression in healthy tissues. BioAtla’s strong intellectual property portfolio, with over 500 issued patents and pending applications covering its CAB technology and product candidates, further supports its market position. The firm continues to invest in its CIAO! manufacturing platform to ensure consistent production of its biologics while relying on third-party contract manufacturers for scale-up.

The company’s customers are primarily pharmaceutical and biotechnology firms that seek to collaborate on clinical development or license its CAB technology. Current partners include Bristol-Myers Squibb, BeiGene, Himalaya Therapeutics, and Context Therapeutics. In addition, BioAtla anticipates serving hospitals, oncology clinics, and patients once its therapeutic candidates receive regulatory approval and reach the market. Until then, its revenue relies on these collaboration agreements rather than direct product sales to end users. The firm also engages contract research organizations and manufacturing organizations as vendors, but these are not considered revenue-generating customers.